# A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

> **NCT06698926** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 110 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ABBV-CLS-616
- **DRUG:** Placebo
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT06698926
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-11
- **Primary completion:** 2026-01-09
- **Final completion:** 2026-01-09
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698926, "A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06698926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*